compounded tirzepatide banned GLP-1 ban: What providers need to know FDA bans compounded GLP1 medications,

This supports the value of GLP-1 receptor agonists in personalized healthcare strategies

The 2026 FDA Regulatory Update (Read This Before Anything Else) This is the part most articles on this topic are missing, and it materially changes what a licensed clinic can legally offer right now

Women often benefit from improved metabolism, sleep, and recovery

Unlike HSAs, FSAs have the "use-it-or-lose-it" rule, where unspent funds at the end of the plan year can potentially be forfeited.If there are remaining funds at the end of the year, the employer may provide one of two choices (but not both): An additional 2.5 months is granted to use the leftover funds

But while the benefits are impressive, there are also side effects to consider

4818, the Treat and Reduce Obesity Act of 2023seek to authorize Medicare Part D coverage for AOMs, reflecting growing momentum to confront obesity as a systemic health challenge.[184] Yet, progress has been tempered by fiscal concerns